Wall Street analysts predict that Biodel Inc. (NASDAQ:ALBO) will report ($0.85) earnings per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Biodel’s earnings, with the highest EPS estimate coming in at ($0.76) and the lowest estimate coming in at ($1.00). The firm is scheduled to announce its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Biodel will report full year earnings of ($3.69) per share for the current year, with EPS estimates ranging from ($4.09) to ($3.38). For the next financial year, analysts forecast that the business will report earnings of ($3.43) per share, with EPS estimates ranging from ($4.60) to ($2.65). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Biodel.

Biodel (NASDAQ:ALBO) last released its earnings results on Monday, August 21st. The biopharmaceutical company reported ($0.86) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.84) by ($0.02).

A number of brokerages have recently commented on ALBO. Wedbush reiterated an “outperform” rating and issued a $58.00 price target on shares of Biodel in a research note on Monday, September 11th. Zacks Investment Research lowered shares of Biodel from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. Cowen and Company began coverage on shares of Biodel in a research note on Wednesday, August 16th. They issued an “outperform” rating for the company. Finally, Needham & Company LLC began coverage on shares of Biodel in a research note on Tuesday, July 18th. They issued a “buy” rating and a $35.00 price target for the company. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Biodel has an average rating of “Buy” and an average price target of $40.33.

An institutional investor recently raised its position in Biodel stock. Renaissance Technologies LLC boosted its holdings in shares of Biodel Inc. (NASDAQ:ALBO) by 0.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 149,632 shares of the biopharmaceutical company’s stock after buying an additional 794 shares during the quarter. Renaissance Technologies LLC’s holdings in Biodel were worth $3,591,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 27.36% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://theolympiareport.com/2017/09/19/0-85-eps-expected-for-biodel-inc-albo-this-quarter.html.

Biodel (ALBO) opened at 22.63 on Tuesday. Biodel has a 1-year low of $11.70 and a 1-year high of $37.69. The stock’s market capitalization is $201.00 million. The firm has a 50-day moving average of $23.61 and a 200-day moving average of $22.46.

Biodel Company Profile

Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.

Get a free copy of the Zacks research report on Biodel (ALBO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Biodel (NASDAQ:ALBO)

Receive News & Ratings for Biodel Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodel Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.